Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single infusion lock in bone gains after osteoporosis treatment?

NCT ID NCT05575167

Ongoing Disease control Sponsor: 424 General Military Hospital Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial investigates whether a single or repeat infusion of zoledronate, or daily oral alendronate, can maintain the bone density improvements achieved with denosumab in postmenopausal women with osteoporosis. Participants who have been on denosumab for at least three years will receive one of the two drugs and be followed for 24 months. The goal is to find the most effective way to prevent bone loss after stopping denosumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zoledronate or alendronate, given as an infusion or oral tablet
What this could lead to
If successful, this could identify the best way to preserve bone density after stopping denosumab, reducing fracture risk in women with osteoporosis.
What could go wrong
This is a mid-stage trial, so results may not apply to all patients. Both drugs carry risks like kidney issues or jaw problems, and the best consolidation strategy is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS, POSTMENOPAUSAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS, POSTMENOPAUSAL

Contacts and locations

Locations

  • , KAT General Hospital

    Athens, 14561, Greece

  • 251 Hellenic Airforce and VA General Hospital

    Athens, 11525, Greece

  • 424 General Military Hospital

    Thessaloniki, 56429, Greece

  • Campus Bio-Medico University

    Roma, 00128, Italy

  • Department of Medicine, Surgery and Neurosciences, University of Siena

    Siena, 53100, Italy

  • First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens

    Athens, 11527, Greece

  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico

    Milan, Italy

  • Univ. Lille, CHU Lille

    Lille, France

  • University-Hospital S. Maria della Misericordia

    Udine, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.